BRPI0615989B8 - formulação farmacêutica de dosagem oral - Google Patents
formulação farmacêutica de dosagem oralInfo
- Publication number
- BRPI0615989B8 BRPI0615989B8 BRPI0615989A BRPI0615989A BRPI0615989B8 BR PI0615989 B8 BRPI0615989 B8 BR PI0615989B8 BR PI0615989 A BRPI0615989 A BR PI0615989A BR PI0615989 A BRPI0615989 A BR PI0615989A BR PI0615989 B8 BRPI0615989 B8 BR PI0615989B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulation
- oral dosage
- dosage pharmaceutical
- guanfacine
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70298205P | 2005-07-28 | 2005-07-28 | |
| US60/702,982 | 2005-07-28 | ||
| PCT/US2006/029277 WO2007016284A2 (en) | 2005-07-28 | 2006-07-27 | Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0615989A2 BRPI0615989A2 (pt) | 2011-05-31 |
| BRPI0615989B1 BRPI0615989B1 (pt) | 2020-05-26 |
| BRPI0615989B8 true BRPI0615989B8 (pt) | 2021-05-25 |
Family
ID=37668083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0615989A BRPI0615989B8 (pt) | 2005-07-28 | 2006-07-27 | formulação farmacêutica de dosagem oral |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070048371A1 (enExample) |
| EP (1) | EP1909766B1 (enExample) |
| JP (2) | JP5726401B2 (enExample) |
| KR (1) | KR20080041669A (enExample) |
| CN (1) | CN101252917A (enExample) |
| AR (1) | AR054595A1 (enExample) |
| AU (1) | AU2006275718B8 (enExample) |
| BR (1) | BRPI0615989B8 (enExample) |
| CA (1) | CA2616181C (enExample) |
| DK (1) | DK1909766T3 (enExample) |
| ES (1) | ES2566395T3 (enExample) |
| IL (1) | IL188980A0 (enExample) |
| NO (1) | NO20081038L (enExample) |
| NZ (1) | NZ565649A (enExample) |
| RU (1) | RU2435573C2 (enExample) |
| TW (1) | TW200744672A (enExample) |
| WO (1) | WO2007016284A2 (enExample) |
| ZA (1) | ZA200801575B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0916163D0 (en) * | 2009-09-15 | 2009-10-28 | Shire Llc | Prodrugs of guanfacine |
| JP6045347B2 (ja) * | 2010-02-03 | 2016-12-14 | ファーマ ツー ビー リミテッド | ラサギリンの持続放出性製剤およびその使用 |
| US20110313046A1 (en) * | 2010-06-11 | 2011-12-22 | Ermer James | Combination therapy with lisdexamphetamine and extended release guanfacine |
| US20120041068A1 (en) * | 2010-08-11 | 2012-02-16 | Aptapharma, Inc. | Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility |
| CN102525983A (zh) * | 2010-12-31 | 2012-07-04 | 北京万全阳光医药科技有限公司 | 胍法新缓释片及其制备方法 |
| CN102579381B (zh) * | 2012-03-30 | 2013-07-10 | 河南中帅医药科技发展有限公司 | 盐酸胍法辛缓释制剂及其制备方法 |
| US9180104B2 (en) * | 2013-03-13 | 2015-11-10 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
| AU2014240988B9 (en) | 2013-03-13 | 2019-01-03 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
| US10022341B2 (en) | 2014-12-02 | 2018-07-17 | Yale University | Methods of preventing neurodegeneration of association cortex in a mammal |
| AU2016368622B2 (en) * | 2015-12-08 | 2022-09-08 | Ardea Biosciences, Inc. | Pharmaceutical composition comprising a potent inhibitor of URAT1 |
| JP6656670B2 (ja) * | 2016-03-11 | 2020-03-04 | 国立大学法人 鹿児島大学 | 抗ｈｃｖ活性を有する薬剤 |
| NZ746669A (en) * | 2016-04-20 | 2022-10-28 | New Frontier Labs Llc | Azelaic acid esters in the treatment of insulin resistance |
| WO2019136224A1 (en) * | 2018-01-05 | 2019-07-11 | Shire Human Genetic Therapies, Inc. | Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders |
| JP2023035359A (ja) * | 2021-09-01 | 2023-03-13 | 東和薬品株式会社 | グアンファシン製剤 |
| EP4292587A1 (en) | 2022-06-15 | 2023-12-20 | Sawai Pharmaceutical Co., Ltd. | Guanfacine hydrochloride containing pharmaceutical preparation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH649918A5 (de) * | 1981-07-09 | 1985-06-28 | Sandoz Ag | Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie. |
| IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
| US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
| DE19834573A1 (de) * | 1998-07-31 | 2000-02-03 | Bayer Ag | Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen |
| FR2781152B1 (fr) * | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
| PE20001396A1 (es) * | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
| US6635277B2 (en) * | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
| US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| WO2003051340A1 (en) * | 2001-12-19 | 2003-06-26 | Astrazeneca Ab | New film coating |
| US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| AU2003224794A1 (en) * | 2002-03-29 | 2003-10-13 | Alza Corporation | Volume efficient controlled release dosage form |
| US6763509B2 (en) * | 2002-09-26 | 2004-07-13 | Sun Microsystems, Inc. | Method and apparatus for allocating decoupling capacitor cells |
| US20070104782A1 (en) * | 2005-07-28 | 2007-05-10 | Ibrahim Melissa E | Modified release tablet formulations with enhanced mechanical properties |
-
2006
- 2006-07-27 CN CNA2006800313902A patent/CN101252917A/zh active Pending
- 2006-07-27 ES ES06788707.5T patent/ES2566395T3/es active Active
- 2006-07-27 NZ NZ565649A patent/NZ565649A/en unknown
- 2006-07-27 DK DK06788707.5T patent/DK1909766T3/en active
- 2006-07-27 JP JP2008524162A patent/JP5726401B2/ja active Active
- 2006-07-27 WO PCT/US2006/029277 patent/WO2007016284A2/en not_active Ceased
- 2006-07-27 AU AU2006275718A patent/AU2006275718B8/en active Active
- 2006-07-27 BR BRPI0615989A patent/BRPI0615989B8/pt active IP Right Grant
- 2006-07-27 KR KR1020087004755A patent/KR20080041669A/ko not_active Withdrawn
- 2006-07-27 RU RU2008102911/15A patent/RU2435573C2/ru active
- 2006-07-27 EP EP06788707.5A patent/EP1909766B1/en active Active
- 2006-07-27 US US11/493,914 patent/US20070048371A1/en not_active Abandoned
- 2006-07-27 CA CA2616181A patent/CA2616181C/en not_active Expired - Fee Related
- 2006-07-28 TW TW095127856A patent/TW200744672A/zh unknown
- 2006-07-28 AR ARP060103292A patent/AR054595A1/es unknown
-
2008
- 2008-01-23 IL IL188980A patent/IL188980A0/en unknown
- 2008-02-18 ZA ZA200801575A patent/ZA200801575B/xx unknown
- 2008-02-27 NO NO20081038A patent/NO20081038L/no not_active Application Discontinuation
-
2012
- 2012-07-17 JP JP2012158337A patent/JP2012229253A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW200744672A (en) | 2007-12-16 |
| AU2006275718B2 (en) | 2012-10-04 |
| US20070048371A1 (en) | 2007-03-01 |
| CA2616181C (en) | 2015-02-17 |
| AU2006275718A1 (en) | 2007-02-08 |
| AR054595A1 (es) | 2007-06-27 |
| RU2008102911A (ru) | 2009-09-10 |
| ES2566395T3 (es) | 2016-04-12 |
| BRPI0615989A2 (pt) | 2011-05-31 |
| JP2009502951A (ja) | 2009-01-29 |
| WO2007016284A2 (en) | 2007-02-08 |
| RU2435573C2 (ru) | 2011-12-10 |
| JP5726401B2 (ja) | 2015-06-03 |
| IL188980A0 (en) | 2008-08-07 |
| CN101252917A (zh) | 2008-08-27 |
| BRPI0615989B1 (pt) | 2020-05-26 |
| CA2616181A1 (en) | 2007-02-08 |
| EP1909766B1 (en) | 2016-03-16 |
| EP1909766A2 (en) | 2008-04-16 |
| ZA200801575B (en) | 2008-12-31 |
| AU2006275718B8 (en) | 2012-11-01 |
| WO2007016284A3 (en) | 2007-03-29 |
| DK1909766T3 (en) | 2016-04-04 |
| NZ565649A (en) | 2011-03-31 |
| JP2012229253A (ja) | 2012-11-22 |
| KR20080041669A (ko) | 2008-05-13 |
| AU2006275718A8 (en) | 2012-11-01 |
| NO20081038L (no) | 2008-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0615989B8 (pt) | formulação farmacêutica de dosagem oral | |
| HRP20181819T1 (hr) | Formulacija krutog farmaceutskog oblika doziranja koja sadrži lopinavir | |
| EP1635762A4 (en) | LOW-DOSED PHARMACEUTICAL POWDER FOR INHALATION | |
| ATE540680T1 (de) | Pharmazeutische aripiprazol-zusammensetzungen | |
| CR20140340A (es) | Formas farmacéuticas de dosificación oral resistente a interferencias que comprenden un analgésico opioide | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| EP2112925A4 (en) | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS | |
| CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| NZ628513A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| CL2007002574A1 (es) | Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson. | |
| CR20110704A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica | |
| CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
| EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
| PL385455A1 (pl) | Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny | |
| JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية | |
| CR8172A (es) | Saquinavir mesilato en forma de dosificacion farmaceutica oral | |
| ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
| IL189827A0 (en) | Pharmaceutical dosage forms and compositions comprising lecoztan | |
| TR200704897A1 (tr) | Uzatılmış salım sağlayan gliklazid formülasyonları@ | |
| BRPI0508855A (pt) | composição farmacêutica de (+) -eritro-mefloquina e seu uso | |
| ATE551998T1 (de) | Feste pharmazeutische zusammensetzung mit tamsulosin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/20 , A61K 9/00 , A61K 31/155 Ipc: A61K 31/155 (1974.07), A61K 31/165 (1974.07), A61K |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: SHIRE LLC (US) Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2640 DE 10/08/2021 POR TER SIDO INDEVIDA. |
|
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |